An Exploratory Examination of Neonatal Cytokines and Chemokines as Predictors of Autism Risk: The Early Markers for Autism Study

Autor: Karen L. Jones, Lisa A. Croen, Judith A Van de Water, Luke Heuer, Paul Ashwood, Robert H. Yolken, Martin Kharrazi, Gerald N. DeLorenze, Cathleen K. Yoshida, Ousseny Zerbo, Robin L Hansen
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Male
Developmental delay
Autism Spectrum Disorder
Developmental Disabilities
Autism
Reproductive health and childbirth
Logistic regression
Medical and Health Sciences
California
0302 clinical medicine
Risk Factors
Neonatal
Medicine
Pediatric
Psychiatry
education.field_of_study
screening and diagnosis
Biological Sciences
Detection
Mental Health
Autism spectrum disorder
Chemokine
Biomarker (medicine)
Cytokines
Female
Chemokines
4.2 Evaluation of markers and technologies
medicine.medical_specialty
Intellectual and Developmental Disabilities (IDD)
Population
Article
03 medical and health sciences
Immune system
Clinical Research
Internal medicine
mental disorders
Humans
Autistic Disorder
education
Cytokine
Biological Psychiatry
business.industry
Prevention
Inflammatory and immune system
Psychology and Cognitive Sciences
Infant
Newborn

Infant
Odds ratio
Perinatal Period - Conditions Originating in Perinatal Period
medicine.disease
Newborn
Confidence interval
Brain Disorders
030104 developmental biology
Early Diagnosis
Logistic Models
Case-Control Studies
Bloodspot
business
030217 neurology & neurosurgery
Biomarkers
Zdroj: Biol Psychiatry
Biological psychiatry, vol 86, iss 4
Popis: Background The identification of an early biomarker for autism spectrum disorder (ASD) would improve the determination of risk, leading to earlier diagnosis and, potentially, earlier intervention and improved outcomes. Methods Data were generated from the Early Markers for Autism study, a population-based case-control study of prenatal and neonatal biomarkers of ASD. Newborn bloodspots of children with ASD (n = 370), children with developmental delay (n = 140), and general population (GP) controls (n = 378) were analyzed for 42 different immune markers using a Luminex multiplex platform. Comparisons of immune marker concentrations between groups were examined using logistic regression and partial least squares discriminant analysis. Results Children with ASD had significantly increased neonatal levels of interleukin-6 (IL-6) and IL-8 compared with GP controls. An increase in IL-8 was especially significant in the ASD group with early onset compared with the GP group, with an adjusted odds ratio of 1.97 (95% confidence interval, 1.39–2.83; p = .00014). In addition, children with ASD had significantly elevated levels of eotaxin-1, interferon-γ, and IL-12p70 relative to children with developmental delay. We observed no significant differences in levels of immune markers between the developmental delay and GP groups. Conclusions Elevated levels of some inflammatory markers in newborn bloodspots indicated a higher degree of immune activation at birth in children who were subsequently diagnosed with ASD. The data from this exploratory study suggest that with further expansion, the development of neonatal bloodspot testing for cytokine/chemokine levels might lead to the identification of biomarkers that provide an accurate assessment of ASD risk at birth.
Databáze: OpenAIRE